CRSP
Price
$41.36
Change
+$0.08 (+0.19%)
Updated
Jun 13 closing price
Capitalization
3.57B
57 days until earnings call
EDIT
Price
$1.97
Change
-$0.21 (-9.63%)
Updated
Jun 13 closing price
Capitalization
164.91M
45 days until earnings call
Interact to see
Advertisement

CRSP vs EDIT

Header iconCRSP vs EDIT Comparison
Open Charts CRSP vs EDITBanner chart's image
CRISPR Therapeutics AG
Price$41.36
Change+$0.08 (+0.19%)
Volume$2.02M
Capitalization3.57B
Editas Medicine
Price$1.97
Change-$0.21 (-9.63%)
Volume$3.05M
Capitalization164.91M
CRSP vs EDIT Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. EDIT commentary
Jun 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and EDIT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 16, 2025
Stock price -- (CRSP: $41.36 vs. EDIT: $1.97)
Brand notoriety: CRSP and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 93% vs. EDIT: 161%
Market capitalization -- CRSP: $3.57B vs. EDIT: $164.91M
CRSP [@Biotechnology] is valued at $3.57B. EDIT’s [@Biotechnology] market capitalization is $164.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $356.66B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 6 TA indicator(s) are bullish while EDIT’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 6 bullish, 4 bearish.
  • EDIT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than EDIT.

Price Growth

CRSP (@Biotechnology) experienced а -1.19% price change this week, while EDIT (@Biotechnology) price change was +3.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

EDIT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (-0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($3.57B) has a higher market cap than EDIT($165M). EDIT YTD gains are higher at: 55.118 vs. CRSP (5.081). EDIT has higher annual earnings (EBITDA): -233.11M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. EDIT (270M). EDIT has less debt than CRSP: EDIT (35M) vs CRSP (219M). CRSP has higher revenues than EDIT: CRSP (35M) vs EDIT (32.3M).
CRSPEDITCRSP / EDIT
Capitalization3.57B165M2,165%
EBITDA-455.24M-233.11M195%
Gain YTD5.08155.1189%
P/E RatioN/AN/A-
Revenue35M32.3M108%
Total Cash1.86B270M687%
Total Debt219M35M626%
FUNDAMENTALS RATINGS
CRSP vs EDIT: Fundamental Ratings
CRSP
EDIT
OUTLOOK RATING
1..100
3633
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9295
PRICE GROWTH RATING
1..100
5539
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (36) in the Biotechnology industry is in the same range as CRSP (65). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (92) in the Biotechnology industry is in the same range as EDIT (95). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (39) in the Biotechnology industry is in the same range as CRSP (55). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (78) in the Biotechnology industry is in the same range as EDIT (100). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPEDIT
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
77%
MACD
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 6 days ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGLYX14.28-0.06
-0.42%
Brookfield Global Listed InfrastructureI
ICTVX9.87-0.06
-0.60%
ICON Utilities and Income Inv
EIVCX13.53-0.10
-0.73%
Allspring Special Large Cap Value C
LGLVX51.07-0.52
-1.01%
Lord Abbett Growth Leaders R6
RLECX19.49-0.38
-1.91%
Russell Inv US Small Cap Equity C

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+0.19%
RXRX - CRSP
73%
Closely correlated
-4.84%
BEAM - CRSP
72%
Closely correlated
-2.18%
NTLA - CRSP
66%
Loosely correlated
-0.48%
PRME - CRSP
64%
Loosely correlated
N/A
ALLO - CRSP
61%
Loosely correlated
-4.29%
More